Document is current
Any future updates will be listed below
-
Authors
Haase, Maximilian
Wittenborn, Esther
-
Funding
Funding for this research was provided by:
Roche Deutschland
- License Information
-
More Information
Article History
Received: 10 March 2026
Accepted: 9 April 2026
First Online: 25 April 2026
Declarations
:
: Maximilian Haase has received speaker honoraria and research support from Roche Pharma AG. Esther Wittenborn is an employee of Roche Pharma AG.
: This research was conducted in full compliance with the Guidelines for Good Pharmacoepidemiology Practice (GPP) published by the International Society of Pharmacoepidemiology ( ), the laws and regulations in Germany as applicable, and the Declaration of Helsinki. The research plan and relevant supporting information was approved by the competent Ethics Committee of the University Rostock on 2 May 2025 (A 2025–0115), before the research was initiated. All patients provided consent for the use and anonymization of the data and explicitly consented to any secondary use of their data.
